New hope for kids with severe eczema: drug trial launches

NCT ID NCT05388760

First seen Oct 31, 2025 · Last updated May 05, 2026 · Updated 26 times

Summary

This study tests a drug called tralokinumab in children aged 6 to 12 with moderate-to-severe eczema. The goal is to see how the drug works in the body and if it is safe. All children will also use moisturizer daily. The study lasts up to 194 weeks with many visits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • LEO Pharma Investigational Site

    Brno, 625 00, Czechia

  • LEO Pharma Investigational Site

    Prague, 150 06, Czechia

  • LEO Pharma Investigational Site

    Reims, Ardennes, 51100, France

  • LEO Pharma Investigational Site

    Rotterdam, 3011 TG, Netherlands

  • LEO Pharma Investigational Site

    Utrecht, 3584 CX, Netherlands

  • LEO Pharma Investigational Site

    Cadiz, Andalusia, 11009, Spain

  • LEO Pharma Investigational Site

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • LEO Pharma Investigational Site

    Alicante, 03010, Spain

  • LEO Pharma Investigational Site

    Manchester, Greater Manchester, M13 9WL, United Kingdom

  • LEO Pharma Investigational Site

    London, SE1 9RT, United Kingdom

  • LEO Pharma Investigational Site

    Sheffield, S10 2TH, United Kingdom

Conditions

Explore the condition pages connected to this study.